ARTICLE | Company News
Valentis cancer, gene/cell therapy news
October 21, 2002 7:00 AM UTC
VLTS will reduce its headcount by up to 45 and aims to reduce its cash expenditure by about $7 million annually. The cuts will enable VLTS to continue the development of its two lead products, Del-1 g...